147 related articles for article (PubMed ID: 38272454)
1. Prognostic value and relapse pattern of HER2-low in hormone receptor-positive breast cancer.
Wei T; Kang Y; Wang X; Yue J; Xu B; Yuan P
Thorac Cancer; 2024 Mar; 15(7):550-558. PubMed ID: 38272454
[TBL] [Abstract][Full Text] [Related]
2. [Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression].
Zhu XJ; Zhang H; Zhang S; Li D; Li X; Xu L; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):243-253. PubMed ID: 37042134
[TBL] [Abstract][Full Text] [Related]
3. HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.
Tan RSYC; Ong WS; Lee KH; Lim AH; Park S; Park YH; Lin CH; Lu YS; Ono M; Ueno T; Naito Y; Onishi T; Lim GH; Tan SM; Lee HB; Ryu HS; Han W; Tan VKM; Wong FY; Im SA; Tan PH; Chan JY; Yap YS
BMC Med; 2022 Mar; 20(1):105. PubMed ID: 35296300
[TBL] [Abstract][Full Text] [Related]
4. Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: A systematic review and meta-analysis.
Ergun Y; Ucar G; Akagunduz B
Cancer Treat Rev; 2023 Apr; 115():102538. PubMed ID: 36898351
[TBL] [Abstract][Full Text] [Related]
5. Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer.
Qiao W; Guo W; Liu Q; Guo X; Deng M
Ann Diagn Pathol; 2023 Jun; 64():152125. PubMed ID: 36822053
[TBL] [Abstract][Full Text] [Related]
6. HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC.
Li JJ; Yu Y; Ge J
Breast Cancer; 2023 May; 30(3):364-378. PubMed ID: 36656510
[TBL] [Abstract][Full Text] [Related]
7. Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer.
Almstedt K; Heimes AS; Kappenberg F; Battista MJ; Lehr HA; Krajnak S; Lebrecht A; Gehrmann M; Stewen K; Brenner W; Weikel W; Rahnenführer J; Hengstler JG; Hasenburg A; Schmidt M
Eur J Cancer; 2022 Sep; 173():10-19. PubMed ID: 35839597
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological Characteristics and Prognosis of HER2-Low Early-Stage Breast Cancer: A Single-Institution Experience.
Xu H; Han Y; Wu Y; Wang Y; Li Q; Zhang P; Yuan P; Luo Y; Fan Y; Chen S; Cai R; Li Q; Ma F; Xu B; Wang J
Front Oncol; 2022; 12():906011. PubMed ID: 35785207
[TBL] [Abstract][Full Text] [Related]
9. Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy.
Kang S; Lee SH; Lee HJ; Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Gong G; Kim HH; Lee S; Lee J; Kim SB
Eur J Cancer; 2022 Nov; 176():30-40. PubMed ID: 36183652
[TBL] [Abstract][Full Text] [Related]
10. Prognostic values of clinical and molecular features in HER2 low-breast cancer with hormonal receptor overexpression: features of HER2-low breast cancer.
Chen M; Chen W; Liu D; Chen W; Shen K; Wu J; Zhu L
Breast Cancer; 2022 Sep; 29(5):844-853. PubMed ID: 35729304
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer.
Ren X; Song Y; Zhang Y; Wu H; Chen L; Pang J; Zhou L; Shen S; Liang Z
BMC Cancer; 2022 May; 22(1):548. PubMed ID: 35568835
[TBL] [Abstract][Full Text] [Related]
12. [Clinicopathological features and prognosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer].
Wang Y; Zhang S; Zhang H; Liang L; Xu L; Cheng YJ; Duan XN; Liu YH; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):853-862. PubMed ID: 36241228
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis.
Molinelli C; Jacobs F; Agostinetto E; Nader-Marta G; Ceppi M; Bruzzone M; Blondeaux E; Schettini F; Prat A; Viale G; Del Mastro L; Lambertini M; de Azambuja E
ESMO Open; 2023 Aug; 8(4):101592. PubMed ID: 37413762
[TBL] [Abstract][Full Text] [Related]
14. The association between HER2-low expression and prognosis of breast cancer: a systematic review and meta-analysis.
Tang Y; Shen G; Xin Y; Li Z; Zheng Y; Wang M; Liu Z; Zhao Y; Zhao F; Ren D; Zhao J
Ther Adv Med Oncol; 2023; 15():17588359231156669. PubMed ID: 36872948
[TBL] [Abstract][Full Text] [Related]
15. Prognosis difference between HER2-low and HER2-zero breast cancer patients: a systematic review and meta-analysis.
Li C; Yuan Q; Deng T; Xu G; Hou J; Zheng L; Wu G
Breast Cancer; 2023 Nov; 30(6):965-975. PubMed ID: 37470943
[TBL] [Abstract][Full Text] [Related]
16. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
Denkert C; Seither F; Schneeweiss A; Link T; Blohmer JU; Just M; Wimberger P; Forberger A; Tesch H; Jackisch C; Schmatloch S; Reinisch M; Solomayer EF; Schmitt WD; Hanusch C; Fasching PA; Lübbe K; Solbach C; Huober J; Rhiem K; Marmé F; Reimer T; Schmidt M; Sinn BV; Janni W; Stickeler E; Michel L; Stötzer O; Hahnen E; Furlanetto J; Seiler S; Nekljudova V; Untch M; Loibl S
Lancet Oncol; 2021 Aug; 22(8):1151-1161. PubMed ID: 34252375
[TBL] [Abstract][Full Text] [Related]
17. HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications.
Tarantino P; Niman SM; Erick TK; Priedigkeit N; Harrison BT; Giordano A; Nakhlis F; Bellon JR; Parker T; Strauss S; Jin Q; King TA; Overmoyer BA; Curigliano G; Regan MM; Tolaney SM; Lynce F
Eur J Cancer; 2022 Oct; 174():277-286. PubMed ID: 36116830
[TBL] [Abstract][Full Text] [Related]
18. Distribution, dynamic evolution, and clinical outcomes of patients with advanced breast cancer according to HER2 expression.
Shi Q; Yu J; Liu D; Ren F; Wu J; Shen K
BMC Cancer; 2023 Feb; 23(1):173. PubMed ID: 36810001
[TBL] [Abstract][Full Text] [Related]
19. New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients.
Yamamura J; Kamigaki S; Fujita J; Osato H; Manabe H; Tanaka Y; Shinzaki W; Hashimoto Y; Komoike Y
BMC Cancer; 2021 Apr; 21(1):476. PubMed ID: 33926418
[TBL] [Abstract][Full Text] [Related]
20. Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis.
Li H; Plichta JK; Li K; Jin Y; Thomas SM; Ma F; Tang L; Wei Q; He YW; Chen Q; Guo Y; Liu Y; Zhang J; Luo S
Breast Cancer Res Treat; 2024 Feb; 204(1):89-105. PubMed ID: 38066250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]